MedTech IGNITE's Roster of Coaches

Mr. Adams became President of the SOLX division of OccuLogix, Inc. on August 31, 2006 with the acquisition of SOLX, a company he founded in 2000. Mr. Adams has an accomplished history in the ophthalmic industry with more than 25 years experience. Mr. Adams has directed the launch of more than 20 products while holding the position of founder and CEO at several start-up companies, in addition to senior executive positions at a variety of companies including Summit Technology, Allergan Medical Optics, and Humphrey Instruments. He holds a BBA from the University of Georgia and has completed executive leadership courses from Columbia University and the Wharton School of Business. He has served on industry advisory boards for Boston University and Ocular Surgery News International.

Mr. Arnold is a seasoned CEO and serial entrepreneur of medical device and life sciences companies who has raised over $120 million in venture capital, IPO and post IPO financings and achieved considerable returns for VC investors through IPO and acquisition while bringing lifesaving technologies to market. Mr. Arnold advises medical device inventors and entrepreneurs on strategy and is active in company formation, financing and strategic partnerships.

From 2001 through early 2005 he was CEO of CardioFocus where he developed a unique endoscopic catheter for treating atrial fibrillation -- now in human trials. In the Spring of 2005 he hired a new CEO and remained as Chairman.

Prior to that in 1993 he founded Cambridge Heart, Inc. (NASDAQ: CAMH), a supplier of cardiology diagnostic equipment, which he took public in a Goldman Sachs led IPO in 1996. He hired a CEO in 2001 and remained as Chairman.

Prior to Cambridge Heart he was CEO of Molecular Simulations, Inc., a $100 MM supplier of software for drug design now called Accelrys (NASDAQ: ACCL). He grew MSI from $10 to $25 MM in two years, then purchased its competitor, BioSym, was sold to Pharmacopeia for $200+ MM and later spun out as Accelrys.

In his early career Mr. Arnold held senior R & D and marketing positions for Becton Dickinson and ran the instrumentation group for medical equipment supplier Datascope Corp during a period of rapid growth from $14 to $40 MM in revenues.

Mr. Arnold is a guest lecturer at the MIT Entrepreneurship Center and Sloan School, a mentor to early stage companies through the MIT Venture Mentoring Society and is on the grant review board at the MIT Deshpande Center. He was formerly Chairman of the Board of the Greater Boston Chapter of the American Heart Association.

Mr. Arnold received a BSEE from MIT in 1972.

Richard Burtt is the Founder and Managing Director of Value Added Strategies (VAS). Mr. Burtt has experience in science, strategic development, management, deal execution, acquisitions, business development, and financial operations. He was most recently the Chief Executive Officer and President of Nomir Medical Technologies (June 2004-December 2009), a company focused on optical solutions to bacterial and fungal diseases in podiatry and dermatology. Earlier in his career, Mr. Burtt was an Executive Vice President of Andover Medical Industries (May 1978-June 1983), a private cardiovascular technology company acquired by Medtronic.

Prior to creating VAS, he co-founded and launched five businesses (Andover Medical, NEMF, IDVehicle, DTAC, Origin Data) leading to their acquisitions. Mr. Burtt developed expertise in corporate development and international marketing as a Vice President for Medtronic (1983-1989). Mr. Burtt holds a MS in Chemical Engineering from the University of Massachusetts (Lowell). In addition, he has over 27 years of experience in Board of Directors memberships and is a Gerson Lehrman Group Council Consultant.

Bill Edelman, is a medical device industry executive with over 32 years experience and currently serves as Chairman of the Board for PolyTouch, Ltd. (general surgical instrumentation), and Stimatix GI (ostomy products). Mr Edelman was most recently President & Chief Executive Officer for TYRX, Inc., a commercial stage venture backed medical device company focused in drug/device implant products for general surgery, electrophysiology and cosmetic surgery. Prior to TYRX, Mr. Edelman has held executive level positions at MicroSense International, LLC (bio-sensing), FibraSonics, Inc. (ultrasonic surgical products), NeuroMod, Inc. (neuro-stimulation technologies), St. Jude Medical, Inc. (NYSE: STJ), Pfizer, Inc. (NYSE: PFE), and Baxter International, Inc. (NYSE: BAX).

Mr. Edelman graduated with a degree in Biomedical Engineering from Rensselaer Polytechnic Institute. He has been issued 15 U.S. patents and is an applicant on 3 additional pending patent applications.

Greg Erman is a proven, serial, medical-technology entrepreneur. He has built four companies from scratch, raised large amounts of venture capital, developed world-class teams, run 150-person P & L operations, and successfully sold two companies at large multiples of investment. Greg was most recently President & CEO of Novo Medical Corporation, a development stage medical device company spun-out of BIDMC producing an EEG-guided noninvasive neurostimulation system to treat brain circuit dysfunctions such as autism and neuropathic pain.

Previously, Greg was President & CEO of Renalworks Medical Corporation, a venture-backed spin-out of MGH and MIT developing an implantable hemofilter for the treatment of ESRD and CHF, which he sold to Fresenius Medical Care in 2007. This followed Greg's work with Partners HealthCare on the commercialization of many new medical device technologies in dozens of clinical fields. Earlier, Greg founded and was President & CEO of MarketSoft Corporation, where he raised $70M in venture capital and led the firm to a prominent position in the marketing automation category, and Waypoint Software Corporation, a VC-backed internet company which he sold to eCommerce leader Open Market Inc. for an annualized 12X return.

Greg holds BSEE and Marketing MBA degrees with high honors from Rutgers University.

Dr. Freeman was president/CEO of HydroCision, Inc., a fluidjet-based medical device company, from 1996 to 2002, when he retired. From 1996 until 2000, he was also Chairman, CEO and a Director of RadioMed Corporation, a developer of medical devices incorporating radioisotopes for inhibition of cellular proliferation.

RadioMed was acquired by IBA in 2000. Prior to 1996, Dr. Freeman was a Principal of Grayson & Associates, an investment banking firm specializing in the healthcare field. Previously, he was president/CEO of Intra-Sonix, Inc. and Xenotech Laboratories, both medical device companies. Still earlier, he was President of Davol, Inc., which was acquired by C. R. Bard, after which he served as a Group Vice President of Bard. Before Davol, he was President of Friesen International, a hospital design firm owned by American Medical International. He was Director, New Business Development for Union Carbide Corp., where he was also General Manager of its clinical diagnostics, radiopharmaceuticals and imaging businesses. Dr. Freeman's early career was as a scientist at Union Carbide.

He holds an ScB from Brown University and a PhD in chemistry from the University of Maryland, and did post-doctoral research in physics at Duke. He is inventor or co-inventor on some 19 US patents. He attended the Harvard Business School Advanced Management Program and has been a Director of numerous companies, public and private, in the healthcare field. He is currently on the board of directors of PhotoBioChem (Leiden, NL), SemiNex (Mass), Medical Record Bank (Mass), Electrolyzer Corporation (Mass) and Pluromed Corporation (Mass). He holds equity in those companies, and is also currently invested in 6 other early-stage ventures. He is on the Executive Board and a member of Boston Harbor Angels, an Angel investment group.

Dr. Golub has been a founding partner and CEO of a number of healthcare companies. He has broad experience in the strategic and execution issues related to bringing medical products to market. In addition, he was also one of the founders of CareStat, a full-service clinical trial consulting company. He is now an independent consultant for the pharmaceutical and medical device industry.

In 1980 Dr. Golub founded PDS Inc., a medical computer-based diagnostic device company where he developed software for automated analysis of infant cardiorespiratory recordings; PDS was acquired in 1995. In 1991 Dr. Golub co-founded Cry Research Inc. where he developed and performed clinical studies utilizing a computer-based signal processing system he developed for automated analysis of the acoustical characteristics of the infant cry. In 1995, he co-founded where technology from his patent was used for a device that permits continuous, cuffless, non-invasive measurement of blood pressure (based on assessment of pulse transit time and photoplethysmographic wave shape). In 1996, he was a founder and President of CareStat Inc., a full service clinical trial consulting company that was acquired in 2005. Dr. Golub has served as Principal Investigator on two large NICHD sponsored studies of infant cry analysis (in relation to SIDS and as a predictor of neurodevelopmental outcome). Dr. Golub has a current appointment at the Harvard-MIT Division of Health Sciences and Technology as Senior Lecturer, is a Distinguished Fellow at the Center for Biomedical Innovation at MIT, and is an adjunct faculty member at Boston University School of Public Health in Epidemiology and Biostatistics.

Dr. Golub earned his M.D. from Harvard Medical School, has a Ph.D. in Bio-Electrical Engineering and an M.S. in Physiological-Psychology from MIT, and received a B.S. in Aerospace Engineering from the University of Virginia.

Mr. McCarty, President of Hawaii Medical, has developed and marketed products for premature babies for more than 20 years. Past president and founder of Children's Medical Ventures, he helped pioneer products to implement Developmental Care in the NICU. For over 25 years, Mr. McCarty has been involved in the development and commercialization of medical devices. His basic research includes work at Boston Children's Hospital in blood separation technologies related to Thalassemia and other blood disorders. Currently, Read travels all over the US to meet with clinicians to discover needs and product improvements for the NICU.

Since joining Hamilton Brook Smith Reynolds, an intellectual property law firm, in 1997, Mary Murray has written and prosecuted patent applications in medical devices, molecular biology, chemistry, polymer science, pharmaceuticals and material sciences; written freedom-to-operate, invalidity, patentability and inventorship opinions, license agreements, intellectual property agreements, confidentiality agreements; prosecuted, enforced and defended trademark applications and registered trademarks; advised clients on trade secret protection of intellectual property; and participated in intellectual property litigation.

Mary was elected to the Board of Directors of MassMEDIC and is an active speaker, moderator, and author on issues relating to intellectual property law practice and the impact on business assets. She has served in a variety of organizational and speaking capacities for Suffolk University Law School and the institution's Center for Advanced Legal Studies.

Before entering law school, Mary was a professor at Tufts University Health Sciences School in the Cell, Developmental and Molecular Biology Program and, from 1994-1995, a Visiting Scientist at the Jackson Laboratory in Bar Harbor, Maine. While at Tufts University, she established a federally funded research program; co-directed a National Institutes of Health sponsored Center; and taught medical, veterinary and graduate school courses. Mary's research areas included molecular biology, biochemistry, chemistry, physiology, protein biochemistry, cell biology, physiology, and developmental biology. Her research program was supported by grants from the National Institutes of Health.

Mary has served on United States Department of Agriculture, National Institutes of Health, and National Science Foundation grant review panels. She was a member of the editorial board of several national and international scientific committees. Mary has authored or co-authored over fifty research publications and given research presentations at national and international scientific conferences, as well as lectures on intellectual property law at universities.

She was summa cum laude at Suffolk University Law School, where she received her law degree. She earned a Ph.D. in Cell and Developmental Biology and a B.S. in Physiology and Biophysics from the University of Illinois.

Prior to becoming CEO of GI Dynamics, Mr. Randle was an Entrepreneur In Residence at Advanced Technology Ventures. Prior to ATV, he was the president and CEO at ACT Medical, Inc., where he was responsible for developing and executing a new strategy that resulted in the sale of the company to MedSource Technologies, Inc. in 2001. Prior to ACT Medical, Mr. Randle was a corporate officer at Allegiance Healthcare Corporation, where he helped plan and execute the spinoff from Baxter International. Previously, he spent 10 years with Baxter in various senior management positions and was responsible for launching the world's first needleless IV system.

Mr. Randle earned an MBA from The Kellogg Graduate School of Management at Northwestern University and a BS in Mechanical Engineering from Cornell University.

Previously CEO of Confluent Surgical, Dr. Sawhney is one of the inventors of the hydrogel technology, which formed the core of Confluent's technology platform. His inventions have formed the basis for the founding of several medical device and biotechnology companies and their products. In addition, other companies that are pursuing technologies that have been co-invented by Dr. Sawhney include Access Closure, Inc. (ACI), Novacell, and Azopax. Dr. Sawhney holds over 55 patents and has authored over 100 publications and scientific abstracts. Prior to co-founding Confluent, Dr. Sawhney was Director and Technology Founder at Focal, Inc. (acquired by Genzyme). In addition to Confluent, he serves on the board of MarketRx Inc. (an Incept company specializing in sales and marketing effectiveness, planning, and analytical products and services) as well as ACI. He currently serves as CEO of I-Therapeutix, a start-up company focusing on in-situ formed hydrogel technologies for ophthalmology.